论文部分内容阅读
目的 :探讨高脂血症时血管活性物质的变化特点及调脂药物gemfibrozil对内皮功能影响的机制。方法 :通过建立大鼠高脂血症模型 ,检测其血TC ,TG ,LDL -C ,HDL -C ,NO ,AngⅡ和VEGF浓度及其在 gemfi brozil治疗 16周后的变化。结果 :与正常对照组比较 ,发现不仅TC ,TG ,LDL -C ,HDL -C浓度升高 ,而且血NO浓度下降 ,VEGF升高 ,但AngⅡ浓度、血压和心脏重量无显著改变。治疗组的TG ,LDL -C显著下降 ,且血NO ,VEGF浓度上升。结论 :高脂血症同样会损害内皮 ,造成内皮功能障碍甚至组织缺血 ,而 gemfibrozil可逆转该改变 ,是降脂之外的作用 ,可能通过VEGF ,NO起效、与AngⅡ浓度无关。
Objective: To investigate the changes of vasoactive substances in hyperlipidemia and the mechanism of the effect of gemfibrozil, a lipid-lowering drug, on endothelial function. Methods: The levels of TC, TG, LDL-C, HDL-C, NO, AngⅡ and VEGF in blood were determined by rat model of hyperlipidemia and their changes after gemfi brozil treatment for 16 weeks. Results: Compared with the normal control group, not only the concentrations of TC, TG, LDL-C and HDL-C were increased, but also the concentration of NO and the level of VEGF were increased. However, Ang II concentration, blood pressure and heart weight were not significantly changed. The treatment group TG, LDL -C significantly decreased, and blood NO, VEGF increased. CONCLUSION: Hyperlipidemia can also damage the endothelium and cause endothelial dysfunction and even tissue ischemia. However, gemfibrozil can reverse this change, which is an extra-lipid-lowering effect. It may play an active role through VEGF and NO, but not with Ang II concentration.